Company news

Ensysce Biosciences, Inc. news in 2026

Ensysce Biosciences, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Ensysce Biosciences Expands Global Investor and Strategic Outreach at Family Office Summit, Dubai

October 21, 2026

Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation

September 15, 2026

Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs

September 14, 2026

Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation

September 2, 2026

Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study

August 31, 2026

Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights

August 13, 2026

Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing

August 6, 2026

Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant

July 14, 2026

Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study

June 26, 2026

Ensysce Biosciences Reports First Quarter 2026 Financial Results

May 15, 2026

Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

May 12, 2026

Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study

April 15, 2026

Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs

April 6, 2026

Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results

March 29, 2026

Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans

March 3, 2026

Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology

March 3, 2026

Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value

February 24, 2026

Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events

February 22, 2026

Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain

January 28, 2026

Ensysce Biosciences Expands Global Opioid Patent Portfolio

January 21, 2026

Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection

January 8, 2026

Ensysce Biosciences Issues Annual Shareholder Letter

January 5, 2026

Calls in 2026

Decks in 2026